Medtronic unveils results from first-in-human study for EV ICD systems
Category: #health  By Saipriya Iyer  Date: 2019-05-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic unveils results from first-in-human study for EV ICD systems

Medtronic plc has reportedly unveiled the results from a test study of its investigational extravascular ICD system, where a lead is positioned outside of the heart and veins to provide anti-tachycardia pacing therapy and lifesaving defibrillations in one system, using a device as big as conventional, transvenous ICDs.
Reportedly, findings from the study were exhibited over a late-breaking session at the 40th Heart Rhythm Session.

Sources claimed that the pilot study, which denotes the first-in-human long-term use of investigational, first-generation system, exhibits that this system could be implanted without any major complications, and can effectively sense, defibrillate, and pace the heart.

Reportedly, the pilot study was conducted on 21 patients across four sites in Australia and New Zealand. Patients were assessed at implant, 2 weeks, 4 to 6 weeks, and 3 months post device’s implantation, and continue to be followed. As per investigators, the defibrillation tests were conducted on 19 patients, at the time of implant. The system effectively terminated induced ventricular arrhythmias in 17 patients, which is steady with previous clinical trials of existing ICDs. Moreover, the pacing capture was accomplished in over 95 percent of study patients. Among which, one individual suffered ventricular tachycardia outside the hospital premises, which was effectively diagnosed and treated through the EV ICD system, cited investigators.

For the record, through EV ICD systems, Medtronic aims to deliver the benefits of conventional, transvenous ICDs comprising anti-tachycardia pacing to tackle arrhythmias; lifesaving defibrillation therapy; post-shock pacing; and provisional back-up, bradycardia pacing to treat unusually slow heart rates. The EV ICD device is fixed in the left mid-axillary area underneath the left armpit, while the lead is positioned below the sternum or breastbone.

The EV ICD system is investigational globally and therefore, not permitted for sale or distribution, reported sources.

Source Credit: https://www.globenewswire.com/news-release/2019/05/11/1822165/0/en/Medtronic-Reveals-Results-of-First-In-Human-Study-for-Investigational-Extravascular-ICD-System.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
By Saipriya Iyer

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac fa...

Alibaba plans to offer bitcoin rewards to shoppers through Lolli
Alibaba plans to offer bitcoin rewards to shoppers through Lolli
By Saipriya Iyer

 

  • Now Alibaba shoppers can earn free bitcoin when they purchase products on Alibaba's e-commerce platform
  • Reportedly, the partnership would enable shoppers...

Daiichi Sankyo announces positive results from Phase 3 pivotal trial
Daiichi Sankyo announces positive results from Phase 3 pivotal trial
By Saipriya Iyer

Daiichi Sankyo Company, Limited (hereafter Daiichi Sankyo), today made a breakthrough announcement stating that the main objective has been achieved from ESAX-DN—a phase 3 pivotal study of esaxerenone—a pro...